Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
NEW INSTRUPHAR from Gent, company number BE0444180618, closed financial year 2025 with a result of € -34,248 after tax. For that financial year NEW INSTRUPHAR recorded a gross margin of € 89,622 and equity of € 445,065. Compared with financial year 2024, the result moved from € -21,628 to € -34,248. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 13, 2026.
€ 445,065
▼ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -34,248
▼ 58 % more loss than in 2024
Profit after tax over the fiscal year.
€ 65,787
▼ 14% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 389,065.
People and assets in 2025
€ 68,676
▲ 7% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 52,726
▼ 25% vs 2024
€ 18,312 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 15,065
▲ 47% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 32,707
▼ 6% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 106,537 | € 82,960 | € 105,648 | € 89,622 | ▼ 15% |
| Profit after taxes | € -28,124 | € -51,041 | € -21,628 | € -34,248 | ▼ € 12,620 |
| Equity | € 581,981 | € 530,941 | € 509,313 | € 445,065 | ▼ 13% |
| Total debts | € 196,153 | € 142,990 | € 117,450 | € 113,517 | ▼ 3% |
| Cash | € 111,681 | € 79,847 | € 76,888 | € 65,787 | ▼ 14% |
| Land & buildings | € 509,104 | € 478,214 | € 450,413 | € 424,257 | ▼ 6% |
| Retained profit | € 525,981 | € 474,941 | € 453,313 | € 389,065 | ▼ 14% |
| Dividend | € 0 | € 0 | € 0 | € 30,000 | |
| Bank debt | € 105,780 | € 88,403 | € 70,721 | € 52,726 | ▼ 25% |
| Balance sheet total | € 849,820 | € 734,244 | € 677,346 | € 599,845 | ▼ 11% |
Key figures of NEW INSTRUPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NEW INSTRUPHAR?
What happened at NEW INSTRUPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 34,248. Source: NBB ↗
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 28,124 loss in 2022 to € 34,248 loss in 2025.
Paid € 24,659 in corporate taxes since 2022.
Paid out € 30,000 in dividends to the owners in total.
Management
Behind NEW INSTRUPHAR is Sophie Cantaert.
Directors
According to the 2025 annual accounts
Sophie Cantaert
Director
Establishments
Establishment units
Physical locations of this company
Brusselsesteenweg 681 box 1
9050 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
Website info
Features
Security
Details
- Company number
- 0444.180.618
- VAT number
- BE 0444.180.618
- Registered office
- Brusselsesteenweg 681 bus 1, 9050 Gent
- Names & denominations
- NEW INSTRUPHAR
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 May 1991
- Peppol
- Active · Active since 5 Jan 2026
- Contact
- newinstruphar.be 09 222 33 90
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen